Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 2006-08, Vol.142 (2), p.366-366 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 366 |
|---|---|
| container_issue | 2 |
| container_start_page | 366 |
| container_title | American journal of ophthalmology |
| container_volume | 142 |
| creator | Bhatt, D.L. Fox, K.A. Hacke, W. Berger, P.B. Black, H.R. Boden, W.E. Cacoub, P. Cohen, E.A. Creager, M.A. Easton, J.D. Flather, M.D. Haffner, S.M. Hamm, C.W. Hankey, G.J. Johnston, S.C. Mak, K.H. Mas, J.L. Montalescot, G. Pearson, T.A. Steg, P.G. Steinhubl, S.R. Weber, M.A. Brennan, D.M. Fabry-Ribaudo, L. Booth, J. Topol, E.J. |
| description | The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events. |
| doi_str_mv | 10.1016/j.ajo.2006.06.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1644940023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939406007203</els_id><sourcerecordid>3556381131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1703-a2f0a5282d8465448a8fa0a13b7d6d556ae639793944736e0705e652921f75bf3</originalsourceid><addsrcrecordid>eNp9UE1LxDAQDaLg-vEDvAU8tyZpmrR4ksUvWPCiFy8h207clG5TJ90F_72pKx6FgeHNvDcfj5ArznLOuLrpctuFXDCm8jmEPCILXuk641XNj8mCMSayuqjlKTmLsUtQaakX5H3Zh9G34QOhp3ZoqY2jRz_QPWDcxT9o-zAAdQHptAE6IuxhmHwYaHDUphKGaYNhuw6Tb-hPM16QE2f7CJe_-Zy8Pdy_Lp-y1cvj8_JulTVcsyKzwjFbikq0lVSllJWtnGWWF2vdqrYslQVV1Hq-XepCAdOsBFWKWnCny7Urzsn1Ye6I4XMHcTJd2OGQVhqupKxler1ILH5gNRhiRHBmRL-1-GU4M7OFpjPJQjNbaOYQMmluDxpI5-89oImNh6GB1iM0k2mD_0f9DccZeTE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1644940023</pqid></control><display><type>article</type><title>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</title><source>Access via ScienceDirect (Elsevier)</source><creator>Bhatt, D.L. ; Fox, K.A. ; Hacke, W. ; Berger, P.B. ; Black, H.R. ; Boden, W.E. ; Cacoub, P. ; Cohen, E.A. ; Creager, M.A. ; Easton, J.D. ; Flather, M.D. ; Haffner, S.M. ; Hamm, C.W. ; Hankey, G.J. ; Johnston, S.C. ; Mak, K.H. ; Mas, J.L. ; Montalescot, G. ; Pearson, T.A. ; Steg, P.G. ; Steinhubl, S.R. ; Weber, M.A. ; Brennan, D.M. ; Fabry-Ribaudo, L. ; Booth, J. ; Topol, E.J.</creator><creatorcontrib>Bhatt, D.L. ; Fox, K.A. ; Hacke, W. ; Berger, P.B. ; Black, H.R. ; Boden, W.E. ; Cacoub, P. ; Cohen, E.A. ; Creager, M.A. ; Easton, J.D. ; Flather, M.D. ; Haffner, S.M. ; Hamm, C.W. ; Hankey, G.J. ; Johnston, S.C. ; Mak, K.H. ; Mas, J.L. ; Montalescot, G. ; Pearson, T.A. ; Steg, P.G. ; Steinhubl, S.R. ; Weber, M.A. ; Brennan, D.M. ; Fabry-Ribaudo, L. ; Booth, J. ; Topol, E.J. ; CHARISMA Investigators</creatorcontrib><description>The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2006.06.024</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>Chicago: Elsevier Inc</publisher><subject>Aspirin ; Confidence intervals ; Drug therapy ; Heart attacks</subject><ispartof>American journal of ophthalmology, 2006-08, Vol.142 (2), p.366-366</ispartof><rights>2006 Elsevier Inc.</rights><rights>Copyright Elsevier Limited Aug 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1703-a2f0a5282d8465448a8fa0a13b7d6d556ae639793944736e0705e652921f75bf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajo.2006.06.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Bhatt, D.L.</creatorcontrib><creatorcontrib>Fox, K.A.</creatorcontrib><creatorcontrib>Hacke, W.</creatorcontrib><creatorcontrib>Berger, P.B.</creatorcontrib><creatorcontrib>Black, H.R.</creatorcontrib><creatorcontrib>Boden, W.E.</creatorcontrib><creatorcontrib>Cacoub, P.</creatorcontrib><creatorcontrib>Cohen, E.A.</creatorcontrib><creatorcontrib>Creager, M.A.</creatorcontrib><creatorcontrib>Easton, J.D.</creatorcontrib><creatorcontrib>Flather, M.D.</creatorcontrib><creatorcontrib>Haffner, S.M.</creatorcontrib><creatorcontrib>Hamm, C.W.</creatorcontrib><creatorcontrib>Hankey, G.J.</creatorcontrib><creatorcontrib>Johnston, S.C.</creatorcontrib><creatorcontrib>Mak, K.H.</creatorcontrib><creatorcontrib>Mas, J.L.</creatorcontrib><creatorcontrib>Montalescot, G.</creatorcontrib><creatorcontrib>Pearson, T.A.</creatorcontrib><creatorcontrib>Steg, P.G.</creatorcontrib><creatorcontrib>Steinhubl, S.R.</creatorcontrib><creatorcontrib>Weber, M.A.</creatorcontrib><creatorcontrib>Brennan, D.M.</creatorcontrib><creatorcontrib>Fabry-Ribaudo, L.</creatorcontrib><creatorcontrib>Booth, J.</creatorcontrib><creatorcontrib>Topol, E.J.</creatorcontrib><creatorcontrib>CHARISMA Investigators</creatorcontrib><title>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</title><title>American journal of ophthalmology</title><description>The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.</description><subject>Aspirin</subject><subject>Confidence intervals</subject><subject>Drug therapy</subject><subject>Heart attacks</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9UE1LxDAQDaLg-vEDvAU8tyZpmrR4ksUvWPCiFy8h207clG5TJ90F_72pKx6FgeHNvDcfj5ArznLOuLrpctuFXDCm8jmEPCILXuk641XNj8mCMSayuqjlKTmLsUtQaakX5H3Zh9G34QOhp3ZoqY2jRz_QPWDcxT9o-zAAdQHptAE6IuxhmHwYaHDUphKGaYNhuw6Tb-hPM16QE2f7CJe_-Zy8Pdy_Lp-y1cvj8_JulTVcsyKzwjFbikq0lVSllJWtnGWWF2vdqrYslQVV1Hq-XepCAdOsBFWKWnCny7Urzsn1Ye6I4XMHcTJd2OGQVhqupKxler1ILH5gNRhiRHBmRL-1-GU4M7OFpjPJQjNbaOYQMmluDxpI5-89oImNh6GB1iM0k2mD_0f9DccZeTE</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Bhatt, D.L.</creator><creator>Fox, K.A.</creator><creator>Hacke, W.</creator><creator>Berger, P.B.</creator><creator>Black, H.R.</creator><creator>Boden, W.E.</creator><creator>Cacoub, P.</creator><creator>Cohen, E.A.</creator><creator>Creager, M.A.</creator><creator>Easton, J.D.</creator><creator>Flather, M.D.</creator><creator>Haffner, S.M.</creator><creator>Hamm, C.W.</creator><creator>Hankey, G.J.</creator><creator>Johnston, S.C.</creator><creator>Mak, K.H.</creator><creator>Mas, J.L.</creator><creator>Montalescot, G.</creator><creator>Pearson, T.A.</creator><creator>Steg, P.G.</creator><creator>Steinhubl, S.R.</creator><creator>Weber, M.A.</creator><creator>Brennan, D.M.</creator><creator>Fabry-Ribaudo, L.</creator><creator>Booth, J.</creator><creator>Topol, E.J.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20060801</creationdate><title>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</title><author>Bhatt, D.L. ; Fox, K.A. ; Hacke, W. ; Berger, P.B. ; Black, H.R. ; Boden, W.E. ; Cacoub, P. ; Cohen, E.A. ; Creager, M.A. ; Easton, J.D. ; Flather, M.D. ; Haffner, S.M. ; Hamm, C.W. ; Hankey, G.J. ; Johnston, S.C. ; Mak, K.H. ; Mas, J.L. ; Montalescot, G. ; Pearson, T.A. ; Steg, P.G. ; Steinhubl, S.R. ; Weber, M.A. ; Brennan, D.M. ; Fabry-Ribaudo, L. ; Booth, J. ; Topol, E.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1703-a2f0a5282d8465448a8fa0a13b7d6d556ae639793944736e0705e652921f75bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aspirin</topic><topic>Confidence intervals</topic><topic>Drug therapy</topic><topic>Heart attacks</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhatt, D.L.</creatorcontrib><creatorcontrib>Fox, K.A.</creatorcontrib><creatorcontrib>Hacke, W.</creatorcontrib><creatorcontrib>Berger, P.B.</creatorcontrib><creatorcontrib>Black, H.R.</creatorcontrib><creatorcontrib>Boden, W.E.</creatorcontrib><creatorcontrib>Cacoub, P.</creatorcontrib><creatorcontrib>Cohen, E.A.</creatorcontrib><creatorcontrib>Creager, M.A.</creatorcontrib><creatorcontrib>Easton, J.D.</creatorcontrib><creatorcontrib>Flather, M.D.</creatorcontrib><creatorcontrib>Haffner, S.M.</creatorcontrib><creatorcontrib>Hamm, C.W.</creatorcontrib><creatorcontrib>Hankey, G.J.</creatorcontrib><creatorcontrib>Johnston, S.C.</creatorcontrib><creatorcontrib>Mak, K.H.</creatorcontrib><creatorcontrib>Mas, J.L.</creatorcontrib><creatorcontrib>Montalescot, G.</creatorcontrib><creatorcontrib>Pearson, T.A.</creatorcontrib><creatorcontrib>Steg, P.G.</creatorcontrib><creatorcontrib>Steinhubl, S.R.</creatorcontrib><creatorcontrib>Weber, M.A.</creatorcontrib><creatorcontrib>Brennan, D.M.</creatorcontrib><creatorcontrib>Fabry-Ribaudo, L.</creatorcontrib><creatorcontrib>Booth, J.</creatorcontrib><creatorcontrib>Topol, E.J.</creatorcontrib><creatorcontrib>CHARISMA Investigators</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhatt, D.L.</au><au>Fox, K.A.</au><au>Hacke, W.</au><au>Berger, P.B.</au><au>Black, H.R.</au><au>Boden, W.E.</au><au>Cacoub, P.</au><au>Cohen, E.A.</au><au>Creager, M.A.</au><au>Easton, J.D.</au><au>Flather, M.D.</au><au>Haffner, S.M.</au><au>Hamm, C.W.</au><au>Hankey, G.J.</au><au>Johnston, S.C.</au><au>Mak, K.H.</au><au>Mas, J.L.</au><au>Montalescot, G.</au><au>Pearson, T.A.</au><au>Steg, P.G.</au><au>Steinhubl, S.R.</au><au>Weber, M.A.</au><au>Brennan, D.M.</au><au>Fabry-Ribaudo, L.</au><au>Booth, J.</au><au>Topol, E.J.</au><aucorp>CHARISMA Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</atitle><jtitle>American journal of ophthalmology</jtitle><date>2006-08-01</date><risdate>2006</risdate><volume>142</volume><issue>2</issue><spage>366</spage><epage>366</epage><pages>366-366</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.</abstract><cop>Chicago</cop><pub>Elsevier Inc</pub><doi>10.1016/j.ajo.2006.06.024</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2006-08, Vol.142 (2), p.366-366 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_journals_1644940023 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | Aspirin Confidence intervals Drug therapy Heart attacks |
| title | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A16%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clopidogrel%20and%20aspirin%20versus%20aspirin%20alone%20for%20the%20prevention%20of%20atherothrombotic%20events&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Bhatt,%20D.L.&rft.aucorp=CHARISMA%20Investigators&rft.date=2006-08-01&rft.volume=142&rft.issue=2&rft.spage=366&rft.epage=366&rft.pages=366-366&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2006.06.024&rft_dat=%3Cproquest_cross%3E3556381131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1644940023&rft_id=info:pmid/&rft_els_id=S0002939406007203&rfr_iscdi=true |